Etavopivat for preventing stroke risk in sickle cell children
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 12 to 16 years old at screening
- Your child has confirmed sickle cell disease (SCD)
- Brain blood-flow test shows high stroke risk (TAMMV at or above 170 cm/s on screening, confirmed twice) and they have never had a primary stroke or certain severe brain vessel problems
- Blood counts are high enough: hemoglobin between 6 and 9 g/dL at screening
- If your child already takes hydroxyurea (HU) for aTCD/cTCD, the dose must be stable for at least 90 days before starting
- If your child can become pregnant, they must use reliable birth control; if male, they must also agree to contraception rules and not donate sperm/eggs during and briefly after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This study measures how well blood flows through brain arteries in children with sickle cell disease using a noninvasive ultrasound test. It may help doctors better understand stroke risk and how treatments like hydroxyurea or recent care affect blood flow.
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
This trial tests whether giving hydroxyurea (a medicine that helps prevent strokes) to children with sickle cell disease who have high-risk blood flow in their brains can stop strokes from happening. It's for kids in Nigeria who are at the peak age for stroke risk (5–12 years old).
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.